Daclacure (Daclatasvir) 60 mg is an oral antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection. It is a direct-acting antiviral (DAA) that targets the NS5A protein, an essential component for HCV replication, effectively preventing the virus from multiplying and spreading in the body.
Daclacure is usually prescribed in combination with Sofosbuvir or other antivirals for a more effective treatment regimen. It is approved for treating HCV genotypes 1, 3, and 4 and is particularly beneficial for patients with compensated cirrhosis or prior treatment failures. The standard dosage is one 60 mg tablet daily, taken orally, with or without food, for 12 to 24 weeks, depending on the patient’s condition and response to therapy.
Common side effects include fatigue, headache, nausea, dizziness, and insomnia. In rare cases, Daclacure may cause serious liver complications, especially in patients with advanced liver disease. Drug interactions should be considered, particularly with medications affecting liver enzymes.
Daclacure is a highly effective and well-tolerated treatment option for hepatitis C, achieving over 95% cure rates when used in combination therapy. Regular liver function tests (LFTs) and medical supervision are essential to ensure safety and effectiveness
Reviews
There are no reviews yet.